+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A new short intensive protocol BL-M-04 for therapy of Burkitt lymphoma in adults: intermediate results

A new short intensive protocol BL-M-04 for therapy of Burkitt lymphoma in adults: intermediate results

Gematologiya i Transfuziologiya 51(6): 3-11

The main aim of the new protocol was to improve the treatment efficiency for patients with Burkitt lymphoma (BL) by intensifying the therapy and contracting the duration of treatment. The study was carried out in 17 patients with the diagnosis of BL (12 men and 5 women aged 5-46 years; mean age 25 years), treated at Hematology Research Center in 2003-2005. Two patients presented with stage I (after S. B. Murphy), one with stage II, six with stage III, and eight with stage IV. Bone marrow involvement was detected in 5, neuroleukemia in 5 patients. The new protocol is based on modified pediatric protocol NHL-BFM-90 with methotrexate dose of 1.5 g/m(2). BL completely regressed in chemosensitive patients after 1-2 blocks irrespective of the initial size of the tumor, and therefore 4 blocks were planned (2 induction and 2 consolidating). The data on the highest sensitivity of the tumor to high-dose methotrexate and cytosar prompted the use of these drugs for the induction phase in order to attain the maximum cytoreducing effect. In order to attain remission, blocks A and C were used. Doxorubicin was added to block A and methotrexate to block C for intensification of therapy. Consolidating courses were similar to the induction ones. The interval between the courses was the same as previously (21 days). Seventeen patients received complete treatment according to BL-M-04 protocol. Remission has been attained in 94% patients; 88% patients are alive during the 1st complete remission (the median of observation 16.5 (5-27) months). Two patients died from chemotherapy complications: 1 from traumatic subdural hematoma in the presence of thrombocytopenia (40 x 10(9)/L) during remission of the underlying disease, the other died from fulminant candidal (Candida krusei) sepsis during remission induction. Total duration of treatment was 3-3.5 months. Unfavorable prognostic factors significantly increasing the number of complications were disease stage IV, ARF by the beginning of therapy, previous treatment, and a history of extensive (mutilating) interventions. We consider that this protocol leads to rapid regression of the tumor and accelerates the treatment due to intensification of chemotherapy with tolerable toxicity.

(PDF emailed within 1 workday: $29.90)

Accession: 012938525

Download citation: RISBibTeXText

Related references

AIDS-associated Burkitt-or Burkitt-like lymphoma The short-term, multiagent and dose intensive B-all protocol is feasible and effective. Blood 102(11): 281a, November 16, 2003

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leukemia & Lymphoma 54(3): 483-490, 2013

Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols. American Journal of Hematology 85(4): 261-263, 2010

A highly therapy-resistant case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma showing strong BCL2 staining, otherwise indistinguishable from Burkitt lymphoma. Journal of Clinical and Experimental Hematopathology 51(1): 37-42, 2011

High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. British Journal of Haematology 126(6): 815-820, 2004

AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leukemia & Lymphoma 47(9): 1872-1880, 2006

Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). Journal of Clinical Oncology 4(6): 847-858, 1986

Improved outcome of adult Burkitt lymphoma patients treated with an intensive pediatric protocol. Blood 84(10 SUPPL 1): 649A, 1994

Short Intensified Therapy and Autologous Stem Cell Transplantation in Adult Burkitt Lymphoma Excellent Results without High-Dose MTX. Blood 100(11): Abstract No 681, November 16, 2002

Burkitt lymphoma A prospective multicenter study of 72 adults treated with the LMB pediatric protocol. Blood 98(11 Part 1): 340a-341a, November 16, 2001

Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Annals of Oncology 16(12): 1928-1935, 2005

Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. Journal of Clinical Oncology 20(12): 2783-2788, 2002

Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience. Terapevticheskii Arkhiv 87(7): 4-14, 2015

Curability of advanced Burkitt's lymphoma in children by intensive short-term chemotherapy. European Journal of Cancer 29A(5): 692-698, 1993